iRhythm Technologies to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences.

• Wolfe Research 2025 Healthcare Conference on Tuesday, November 18, 2025, at 9:20 a.m. Eastern Time (6:20 a.m. Pacific Time)
• Jefferies 2025 Global Healthcare Conference on Thursday, November 20, 2025, at 9:30 a.m. Greenwich Mean Time (1:30 a.m. Pacific Time)
• Citi 2025 Global Healthcare Conference on Wednesday, December 03, 2025, at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time)
• Evercore 8th Annual Healthcare Conference on Thursday, December 04, 2025, at 9:10 p.m. Eastern Time (6:10 a.m. Pacific Time)

Interested parties may access live and archived webcasts of the presentations on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com.

About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all. For additional information about iRhythm, please visit its corporate website at irhythmtech.com.

Investor Contact
Stephanie Zhadkevich
investors@irhythmtech.com

Media Contact
Kassandra Perry
irhythm@highwirepr.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.